Cell Line Development Market Size By Product [Reagents & Media, Equipment (Incubator, Centrifuge, Bioreactor, Storage equipment, Microscope), Accessories & Consumables], By Source [Mammalian, Non-Mammalian (Insects, Amphibians)], By Cell Line [Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line], By Application [Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research] Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, China, India, Japan, Brazil, Mexico, South Africa), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023
Published Date: May 2016 | 149 Pages | Report ID: GMI429 Report Format: PDF
Cell Line Development Market size was accounted to be over USD 2.8 Bn in 2015 with 13.0% CAGR estimation over forecast period of 2016 to 2023.
UK Cell Line Development Market size, by Product, 2012-2023 (USD Million)
The cell line development market is observing increasing need for monoclonal antibodies (MAbs). As of 2014 in the U.S. and Europe more than 46 monoclonal antibody products have accepted, as per data published by the NCBI, and considering existing approval rate over every year 65 MAbs will be available in market by 2020.
Termination of patents of several blockbuster biologics accompanied by growing demand for novel biosimilars, vaccines, drugs, and therapeutic proteins, is one of the crucial aspects boosting the growth of global cell line development market size.
Growing prevalence of cancer is additional significant factor leading to the development of market over the forecast period. Growth in research activities related to cancer is likely to generate more need for cell lines, driving the growth of cell line development market. As per WHO, worldwide cancer occurrences in 2012 were over 13.8 million, of those 7.3 million male patients and 6.5 million females.
Introduction of several modalities and rising number of MAbs-based viable therapies are foremost factors that are likely to drive the growth of cell line development market. In accumulation to this, technological improvements in MAbs development leading into advanced product yield with improved cost-efficiency, would act as a catalyst for growth of cell line development market. However, complex regulatory landscape has indirectly affected the investors of cell line development as regulations play an important role in approval of various products and failure to approve will eventually lead to loss for the investor.
Cell Line Development Market, By Product
Reagents and media accounted for major market share in 2015, with around USD 1.5 billion and is likely to continue to do so over the forecast period. Increased use of reagents and media in procedures such as regenerative medicines, drug discovery, bio production, toxicity testing, research, and tissue engineering, are some key factors bolstering the growth of this product segment. Additionally, reagent and media are essential constituent of cell line development & cell culture procedures and are cost intensive in nature.
Equipment product segment accounted for 41.4% market share in 2015 and will lose market share to accessories and consumables product segment over the forecast period. The segment is predicted to grow from USD 1,1 billion in 2015 to over USD 3 billion by 2023. Equipment product segment is further classified into five segments as incubators, centrifuges, bioreactors, storage equipment, microscopes. Out of that incubators sub segment is predicted to grow at a highest CAGR of 13.5% while bioreactors sub segment is likely to account for maximum market share of 31.3% by 2023.
The accessories and consumables product segment is probable to witness highest growth rate of 16.3% over the forecast period due to growing use of disposables for production of monoclonal antibodies and vaccines.
Cell Line Development Market, By Source
Mammalian cells are delicate since they are roughly around 15- to 45-fold bigger than microbial cells, in absence of the tough cell walls of microbes, and these are very vulnerable to impurities. Merely getting these cells to develop and reproduce in culture is itself a challenge. The unique and essential aspects of mammalian cell culture characteristics, cell metabolism, growth kinetics, process monitoring and control, bioreactor development, and process issues in largescale mammalian cell cultures.
Improved engineering and expression systems for mammalian cell source development are likely to bolster the market growth. At present, over 4,000 mammalian lines are available in market and on-going research activities are likely to introduce a few more. The mammalian source segment for cell line development accounted for maximum market share in 2015 owing to its ability to express complex proteins similar to that of human beings and growing adoption rates to produce monoclonal antibodies.
The Non-mammalian source segment accounted for over 25% market share through out the forecast period. The segment is further sub segment into insects and amphibians.
Cell Line Development Market, By Cell Line
Recombinant cell line development market accounted for highest share in 2015 and is likely to lose market share to hybridomas and primary cell lines segment over the forecast period.
Hybridoma cells are developed in mini-fermenters based on dialysis. The technique produces high density cultures that can be over 15 to 25 times that attained in static cell culture systems. Hybridomas cells are grown at maximum density in roller bottles or culture flasks. The segment accounted for second highest in terms of market share over the forecast period, the antibody-containing conditioned medium is sterile filtered recovered, and frozen. Antibody concentration can vary greatly, depending on the specific hybridoma, but averages between 20 and 40 ug/ml.
Cell Line Development Market, By Application
By application the industry is segment as bioproduction, toxicity testing, drug discovery, tissue engineering, and research. Bioproduction of vaccines and antibiotics is the foremost application area, expected to exceed USD 3 billion by 2023. Bioproduction was accounted for highest market value in 2015 of USD 1,306.0 million followed by toxicity testing, that measured for 598.3 million. Growing incidence and prevalence of chronic ailments like autoimmune diseases and cancer is leading the need for effective and rapid acting therapeutics, and this is expected to grow robustly in future due to rise of communicable diseases and epidemic particularly in the emerging economies.
Moreover, an increase in research and development activities, availability of technically progressive procedures and the introduction of biosimilars for large scale manufacturing of biologics are likely to bolster the growth the segment, over the forecast period.
Cell Line Development Market, By Region
North America dominated the global for cell line development market. Characterised by presence of increasing demand for biologics, enhanced healthcare infrastructure, and growing awareness related to cell therapy in the U.S. are few factors driving the market over the forecast period. The U.S. cell line development market is estimated to account for over 85% market throughout the forecast period.
In Asia Pacific, presence of improved economic development, untapped opportunities, developing healthcare infrastructure, and favourable policies by government and manufacturers in biotechnology division are few key factors leading to rapid growth in China cell line development market. Coupled with substantial investments by multinational companies in countries such as China and India will make the market grow at attractive CAGR.
Latin America cell line development market is likely to grow at a significant CAGR of 13.3% over he forecast period. Brazil, especially is likely to be emerging as promising market for cell line development due to ease of access and transport from U.S.
Competitive Market Share
Market is competitive in nature and dominated by limited number of players. WuXi AppTec Inc., Corning Inc., Thermo Fisher Scientific, Inc., Selexis SA, Sigma Aldrich Corporation, European Collection of Cell Cultures (ECACC), Sartorious AG, GE Healthcare, American Type Culture Collection (ATCC), and Lonza Group AG are companies operating in cell line development market. Functional companies present in this markets are striving to gain competitive advantage via capitalizing on available untapped opportunities.
Cell Line Development Industry Background
Technological advancements and innovation motivate the global market. Companies are investing enormously in research and development processes to offer distinguished resolutions to increase their current market share. Presence of extensive product offerings and strategic initiatives mark the market such as the collaborative agreement, to maintain leadership position. The cell line development industry is competitive in nature characterized by intense competition.
What Information does this report contain?
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security